Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Dapirolizumab Pegol in Healthy Japanese and Caucasian Participants
NCT04571424Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dapirolizumab pegol in systemic lupus erythematosus (SLE) (3 arms), sponsored by Biogen. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Oct 2020; status: completed.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04571424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571424.